Value of Biopsy Data in HL

The diagnostic and relapse biopsies, as well as clinical outcome data were compared in this study to determine the biology associated with resistance to first-line therapy in Hodgkin lymphoma (HL), as well as identify prognostic markers. Findings were presented at the 2014 American Society of Hematology annual meeting. Biopsies (n = 245) were sampled from 174 patients with classical HL.

Inferior post-high-dose chemotherapy and autologous stem cell transplantation failure-free survival were seen in patients with poorly correlated biopsy pairs (five-year failure-free survival: poorly correlated 39% versus well correlated 68%; log-rank p = 0.005).

Read more here.


Global Database

Information by country, region and/or subtype on treatments, clinical trials and incidence/mortality rates.

Resource Library

Over 2,000 pieces of information on lymphoma diagnosis, treatment, research, support and lifestyle.

logo europe


Are you aware cancer patients can experience chemo brain without ever receiving chemotherapy?




The information on this website is for general use only. Please consult your physician if you think you may have lymphoma or
require more detailed information on the best course of treatment for you.

Our website does not host any form of advertisement. Last updated: 03/27/18. Copyright © 2018 Lymphoma Coalition. All rights reserved.